MedTrace Logo

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

NCT03346837 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2018-02-28

No results posted yet for this study

Summary

Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.

Conditions

  • Malignancies Multiple

Interventions

DRUG

BMS-986205

BMS-986205

DRUG

Itraconazole

Oral solution

DRUG

Rifampin

Tablet

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Briston-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2017-12-20
Completion
2017-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346837 on ClinicalTrials.gov